Gotham Asset Management LLC Sells 25,965 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Gotham Asset Management LLC reduced its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 28.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 64,948 shares of the company's stock after selling 25,965 shares during the period. Gotham Asset Management LLC owned about 0.14% of Pacira BioSciences worth $1,224,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Corton Capital Inc. boosted its position in shares of Pacira BioSciences by 6.0% during the 4th quarter. Corton Capital Inc. now owns 21,575 shares of the company's stock valued at $406,000 after acquiring an additional 1,214 shares in the last quarter. BOKF NA acquired a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $562,000. Bridgeway Capital Management LLC boosted its position in shares of Pacira BioSciences by 3.2% during the 4th quarter. Bridgeway Capital Management LLC now owns 358,785 shares of the company's stock valued at $6,760,000 after acquiring an additional 11,149 shares in the last quarter. Brevan Howard Capital Management LP acquired a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $637,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Pacira BioSciences during the 4th quarter valued at about $8,180,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PCRX has been the topic of several recent research reports. Needham & Company LLC decreased their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. HC Wainwright lifted their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their price target for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Barclays boosted their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Pacira BioSciences has an average rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Price Performance

NASDAQ:PCRX traded down $0.32 on Friday, reaching $25.75. The stock had a trading volume of 477,629 shares, compared to its average volume of 972,523. The company has a market capitalization of $1.19 billion, a P/E ratio of -12.68 and a beta of 0.56. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.64. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock has a fifty day moving average price of $25.21 and a 200-day moving average price of $22.69.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.